A Study of TYRA-300 in Children With Achondroplasia: BEACH301
← catalyst calendarNCT06842355 · readout ≤ 1,260 d
Sponsored by Tyra Biosciences, Inc (industry) · TYRA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
92estimated
Sites
24
Countries
Australia, Canada, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-04 | actual | When the study began enrolling |
| Primary completion | Jan 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Interventions
- Drug: TYRA-300 0.125 mg/kg
- Drug: TYRA-300 0.25 mg/kg
- Drug: TYRA-300 0.375 mg/kg
- Drug: TYRA-300 0.50 mg/kg
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-related adverse events as assessed by CTCAE v5.0
measured Up to 12 months
Change from baseline in annualized growth velocity (Cohort 1)
measured 12 months
Permalink · TYRA's whole pipeline · Catalyst calendar · Every registered study · What changed